156 related articles for article (PubMed ID: 35211085)
1. Long-Term Improvement in a Chinese Cohort of Glucocorticoid-Resistant Childhood-Onset Myasthenia Gravis Patients Treated With Tacrolimus.
Bi Z; Cao Y; Lin J; Zhang Q; Liu C; Gui M; Bu B
Front Neurol; 2022; 13():820205. PubMed ID: 35211085
[TBL] [Abstract][Full Text] [Related]
2. Long-term efficacy and safety of tacrolimus in young children with myasthenia gravis.
Zhang Y; Zhang M; Zhang L; Zhou S; Li W
J Clin Neurosci; 2023 Oct; 116():93-98. PubMed ID: 37669613
[TBL] [Abstract][Full Text] [Related]
3. Tacrolimus in the treatment of myasthenia gravis in patients with an inadequate response to glucocorticoid therapy: randomized, double-blind, placebo-controlled study conducted in China.
Zhou L; Liu W; Li W; Li H; Zhang X; Shang H; Zhang X; Bu B; Deng H; Fang Q; Li J; Zhang H; Song Z; Ou C; Yan C; Liu T; Zhou H; Bao J; Lu J; Shi H; Zhao C
Ther Adv Neurol Disord; 2017 Sep; 10(9):315-325. PubMed ID: 28861121
[TBL] [Abstract][Full Text] [Related]
4. Remission and relapses of myasthenia gravis on long-term tacrolimus: a retrospective cross-sectional study of a Chinese cohort.
Bi Z; Cao Y; Liu C; Gui M; Lin J; Zhang Q; Li Y; Ji S; Bu B
Ther Adv Chronic Dis; 2022; 13():20406223221122538. PubMed ID: 36093262
[TBL] [Abstract][Full Text] [Related]
5. Comparative effectiveness and safety of intravenous methylprednisolone and tacrolimus monotherapy in ocular myasthenia gravis with unsatisfactory prednisone responses: a retrospective study.
Zhang KY; Duan WW; Luo YB; Li Y; Hu J; Yang H
Orphanet J Rare Dis; 2024 Jan; 19(1):19. PubMed ID: 38243274
[TBL] [Abstract][Full Text] [Related]
6. Effect of tacrolimus on soluble costimulatory molecules in patients with refractory myasthenia gravis.
Wu H; Chen L; Zhou X; Wu Y; Yan Y; Zhu Y; Zhao C; Xue Q
J Neuroimmunol; 2022 Nov; 372():577955. PubMed ID: 36054935
[TBL] [Abstract][Full Text] [Related]
7. Tacrolimus Improves Symptoms of Children With Myasthenia Gravis Refractory to Prednisone.
Liu C; Gui M; Cao Y; Lin J; Li Y; Ji S; Bu B
Pediatr Neurol; 2017 Dec; 77():42-47. PubMed ID: 29074055
[TBL] [Abstract][Full Text] [Related]
8. Correlation of Quantitative Myasthenia Gravis and Myasthenia Gravis Activities of Daily Living scales in the MGTX study.
McPherson T; Aban I; Duda PW; Farzaneh-Far R; Wolfe GI; Kaminski HJ; Cutter G; Lee I;
Muscle Nerve; 2020 Aug; 62(2):261-266. PubMed ID: 32369631
[TBL] [Abstract][Full Text] [Related]
9. Clinical efficacy of tacrolimus for treating myasthenia gravis and its influence on lymphocyte subsets.
Bao J; Gao S; Weng Y; Zhu J; Ye H; Zhang X
Rev Neurol (Paris); 2019; 175(1-2):65-72. PubMed ID: 30293884
[TBL] [Abstract][Full Text] [Related]
10. Long-term efficacy and safety of leflunomide combined with low-dose prednisone in treatment of myasthenia gravis: a retrospective study.
Qiu L; Chen P; Ou C; Deng J; Huang Z; Lin Z; Ma Q; Huang X; Yu L; Ran H; Liu W
Acta Neurol Belg; 2024 Feb; 124(1):175-182. PubMed ID: 37656361
[TBL] [Abstract][Full Text] [Related]
11. Efficacy and safety of tacrolimus as long-term monotherapy for myasthenia gravis.
Itani K; Nakamura M; Wate R; Kaneko S; Fujita K; Iida S; Morise S; Murakami A; Kunieda T; Takenouchi N; Yakushiji Y; Kusaka H
Neuromuscul Disord; 2021 Jun; 31(6):512-518. PubMed ID: 33903022
[TBL] [Abstract][Full Text] [Related]
12. Therapeutic and Immunoregulatory Effects of Tacrolimus in Patients with Refractory Generalized Myasthenia Gravis.
Wu H; Wang Z; Xi J; Liu J; Yan C; Song J; Wang L; Jing S; Wang Y; Zhao C
Eur Neurol; 2020; 83(5):500-507. PubMed ID: 32932253
[TBL] [Abstract][Full Text] [Related]
13. Comparison between mono-tacrolimus and mono-glucocorticoid in the treatment of myasthenia gravis.
Fan Z; Lei L; Su S; Zhang S; Xie N; Li L; Lu Y; Di L; Wang M; Xu M; Shen XM; Da Y
Ann Clin Transl Neurol; 2023 Apr; 10(4):589-598. PubMed ID: 36808840
[TBL] [Abstract][Full Text] [Related]
14. Efficacy and safety of tacrolimus in Osserman grade III and Osserman grade IV Myasthenia Gravis.
Zhao LN; Liang Y; Fang XJ; Liu XM; Jiang QL; Wang SS; She SF; Cao M
Clin Neurol Neurosurg; 2018 Oct; 173():70-76. PubMed ID: 30092406
[TBL] [Abstract][Full Text] [Related]
15. Evaluation of outcome measures for myasthenia gravis subgroups.
Luo Y; Dong X; Peng Y; Cui B; Yan C; Jin W; Li Y; Zhou R; Huang K; Yang H
J Clin Neurosci; 2021 Sep; 91():270-275. PubMed ID: 34373039
[TBL] [Abstract][Full Text] [Related]
16. Tacrolimus as Single-Agent Immunotherapy and Minimal Manifestation Status in Nonthymoma Myasthenia Gravis.
Duan W; Peng Y; Jin W; Ouyang S; Yang H
J Immunol Res; 2021; 2021():9138548. PubMed ID: 34845439
[TBL] [Abstract][Full Text] [Related]
17. QMG and MG-ADL correlations: Study of eculizumab treatment of myasthenia gravis.
Howard JF; Freimer M; O'Brien F; Wang JJ; Collins SR; Kissel JT;
Muscle Nerve; 2017 Aug; 56(2):328-330. PubMed ID: 28010051
[TBL] [Abstract][Full Text] [Related]
18. Long-term outcome of 424 childhood-onset myasthenia gravis patients.
Gui M; Luo X; Lin J; Li Y; Zhang M; Zhang X; Yang M; Wang W; Bu B
J Neurol; 2015; 262(4):823-30. PubMed ID: 25588729
[TBL] [Abstract][Full Text] [Related]
19. Efficacy and Safety of Tacrolimus Therapy for a Single Chinese Cohort With Very-Late-Onset Myasthenia Gravis.
Zheng Y; Yuan X; Zhang C; Liu R; Jin H; Hao H; Li F; Zhao Y; Yuan Y; Wang Z; Gao F
Front Neurol; 2022; 13():843523. PubMed ID: 35432159
[TBL] [Abstract][Full Text] [Related]
20. Leflunomide treatment in corticosteroid-dependent myasthenia gravis: an open-label pilot study.
Chen P; Feng H; Deng J; Luo Y; Qiu L; Ou C; Liu W
J Neurol; 2016 Jan; 263(1):83-8. PubMed ID: 26514837
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
